Recent News for BVXV - BiondVax Pharmaceuticals Ltd.

Date Title
Jul 13 Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q2 Estimates
Jul 10 The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Jul 9 The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Jul 7 The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold
Jul 1 Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
Jun 30 Biondvax Pharmaceuticals EPS beats by $0.01
Jun 30 BiondVax Announces First Quarter 2020 Financial Results
Jun 16 BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…
Jun 12 Biondvax Pharmaceuticals reports FY results
Jun 12 BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Jun 10 NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
May 22 The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
May 21 The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
May 20 BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
May 19 The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
May 9 How BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Can Impact Your Portfolio Volatility
May 4 BiondVax Announces Upcoming Expiration of Public Warrants
Apr 29 82 Stocks Moving In Wednesday's Mid-Day Session
Mar 24 New Directors Elected to BiondVax's Board of Directors
Mar 19 BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial
Feb 5 Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
Jan 16 BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis
Jan 15 HEXO, NKTR, OGI and ACOR among midday movers
Jan 15 Healthcare - Top 5 Gainers / Losers

Back to the Main BVXV Page...